Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer.

International journal of molecular sciences - 9 Jul 2016

Binder Moritz, Zhang Ben Y, Hillman David W, Kohli Rhea, Kohli Tanvi, Lee Adam, Kohli Manish

Abstract excerpt

Treatment with abiraterone acetate and prednisone (AA/P) prolongs survival in metastatic castration-resistant prostate cancer (mCRPC) patients. We evaluated the genetic variation in CYP17A1 as predictive of response to AA/P. A prospective collection of germline DNA prior to AA/P initiation and follow-up of a mCRPC cohort was performed. Five common single-nucleotide polymorphisms (SNPs) in CYP17A1 identified using...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Kaplan-Meier Estimate
Share to Logistic Models

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Odds Ratio

Share to Prednisone

Share to Proportional Hazards Models

Share to Prostate-Specific Antigen

Share to Prostatic Neoplasms, Castration-Resistant

Share to Steroid 17-alpha-Hydroxylase

Source

Open in PubMed Open full text

Identifiers

PMID: 27409606
DOI: 10.3390/ijms17071097
PMCID: PMC4964473

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer.PMID 27409606Read ↗

CYP17A1 polymorphisms and clinical outcome of castration-resistant prostate cancer patients treated with abiraterone.Semantic proximity Read ↗

CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone.Semantic proximity Read ↗

<i>HSD3B1</i> genotype among metastatic castration-resistant prostate cancer patients: pharmacodynamics and clinical outcomes after treatment with abiraterone plus prednisoneSemantic proximity Read ↗

Connecting Gene Variation to Treatment Outcomes in Metastatic Castration-Resistant Prostate Adenocarcinoma: Insights into Second-Generation Androgen Receptor Axis-Targeted Therapies.Semantic proximity Read ↗

The association between missense polymorphisms in SRD5A2 and HSD3B1 and treatment failure with abiraterone for castration-resistant prostate cancer.Semantic proximity Read ↗

Association of Missense Polymorphism inHSD3B1With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or AbirateroneSemantic proximity Read ↗

HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studiesSemantic proximity Read ↗

Genetic variations predicting progression with docetaxel and novel androgen-receptor pathway inhibitors.Semantic proximity Read ↗

Germline predictors of androgen deprivation therapy response in advanced prostate cancer.Semantic proximity Read ↗

Genetic polymorphisms of CYP17A1 in steroidogenesis pathway are associated with risk of progression to castration-resistant prostate cancer in Japanese men receiving androgen deprivation therapy.Semantic proximity Read ↗

Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype.Semantic proximity Read ↗

Molecular markers in sex hormone pathway genes associated with the efficacy of androgen-deprivation therapy for prostate cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.